Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults - Contacts and Locations

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

This study has been suspended.
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00413725

Locations


South Africa
	Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital
	Johannesburg, South Africa
	Aurum Institute for Health, KOSH District
	Klerksdorp, South Africa
	Cape Town HVTU
	Mowbray, South Africa
	Centre for the AIDS Program of Research in South Africa (CAPRISA)
	Congella, South Africa
	Medunsa HIV Research Unit
	Medunsa, South Africa, 0204 SF

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

HIV Vaccine Trials Network

Investigators


Study Chair:	Glenda Gray, MD	Chris Hani Baragwanath Hospital

Study Chair:	James Kublin, MD, MPH	Fred Hutchinson Cancer Research Center